Optimizing cancer care: Is the future bright?

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 3, 2011, Pages 347-350

  Zahedi, P ^a   De Souza, R ^a   Piquette Miller, M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHLORMETHINE; CYTOTOXIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER THERAPY; CHILDHOOD LEUKEMIA; COGNITIVE DEFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MONITORING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT PLANNING;

FORECASTING; HUMANS; NEOPLASMS;

EID: 80052008582     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.167     Document Type: Review

References (19)

1. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. & Forman, D. Global cancer statistics. CA-Cancer J. Clin. 61, 69-90 (2011).
2. DeVita, V.T. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643-8653 (2008).
3. Sparreboom, A. & Verweij, J. Advances in cancer therapeutics. Clin. Pharmacol. Ther. 85, 113-117 (2009).
4. Fardell, J.E., Vardy, J., Johnston, I.N. & Winocur, G. Chemotherapy and cognitive impairment: treatment options. Clin. Pharmacol. Ther. 90, 366-376 (2011).
5. Pachman, D.R., Barton, D.L., Watson, J.C. & Loprinzi, C.L. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin. Pharmacol. Ther. 90, 377-387 (2011).
6. Paugh, S.W., Stocco, G., McCorkle, J.R., Diouf, B., Crews, K.R. & Evans, W.E. Cancer pharmacogenomics. Clin. Pharmacol. Ther. 90, 461-466 (2011).
7. Coussens, L.M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002). (Pubitemid 36019639)
8. Clarke, S.J. et al. Use of inflammatory markers to guide cancer treatment. Clin. Pharmacol. Ther. 90, 475-478 (2011).
9. Baird, R.D., Tan, D.S.P. & Kaye, S.B. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat. Rev. Clin. Oncol. 7, 575-582 (2010).
10. Pasquier, E., Kavallaris, M. & Andre, N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7, 455-465 (2010).
11. Vassileva, V. et al. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br. J. Cancer 99, 2037-2043 (2008).
12. De Souza, R., Zahedi, P., Moriyama, E.H., Allen, C.J., Wilson, B.C. & Piquette-Miller, M. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol. Cancer. Ther. 9, 1820-1830 (2010).
13. De Souza, R., Zahedi, P., Badame, R.M., Allen, C.J. & Piquette-Miller, M. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol. Cancer. Ther. 10, 1289-1299 (2011).
14. Kodama, A., To, H., Kinoshita, T., Ieiri, I. & Higuchi, S. Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. J. Pharm. Pharmacol. 61, 615-621 (2009).
15. Xiang, X.X., Sui, M.H., Fan, W.M. & Kraft, A.S. Cell cycle-dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol. Ther. 6, 1067-1073 (2007). (Pubitemid 351574958)
16. US Food and Drug Administration. Cancer Drug Approval Endpoints . Accessed 17 June 2011.
17. Ward, E. et al. Association of insurance with cancer care utilization and outcomes. CA-Cancer J. Clin. 58, 9-31 (2008).
18. Klamerus, J.F. et al. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin. Cancer Res. 16, 5997-6003 (2010).
19. US Food and Drug Administration. Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination (December 2010).